Islet alterations in type 2 diabetes
2 型糖尿病中的胰岛改变
基本信息
- 批准号:10554283
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAlpha CellBeta CellBindingCell physiologyCellsChIP-seqColorDataDefectDiabetes MellitusDiseaseEnvironmentExposure toFunctional disorderGLP-I receptorGene ExpressionGene Expression RegulationGenesGenetic TranscriptionGlucagonGrantHealthcare SystemsHepaticHormonesHumanHyperglycemiaImmunodeficient MouseImmunologic Deficiency SyndromesImpairmentIn VitroIndividualInsulinInsulin ResistanceInvestigationIslet CellIslets of LangerhansKnockout MiceKnowledgeMaintenanceModelingMolecularMusNon-Insulin-Dependent Diabetes MellitusParacrine CommunicationPathogenesisPlayProcessProductionRodentRodent ModelRoleSamplingSystemTestingTranscriptional RegulationTransplantationVeteransclinically actionableclinically relevantcommon treatmentexenatidefunctional improvementgene productgenetic manipulationglucagon-like peptide 1glucose productionhuman modelimprovedin vivoinnovationinsulin secretionisletknock-downmouse modelnew technologynon-diabeticsingle cell sequencingsmall hairpin RNAtranscription factortranscription regulatory networktranscriptome
项目摘要
Type 2 diabetes mellitus (T2D), a formidable and growing challenge to the VA healthcare system, represents a
heterogenous set of hyperglycemic disorders involving impaired insulin secretion, insulin resistance, and
increased hepatic glucose production. Both insufficient insulin secretion from β cells and dysregulated, typically
increased, glucagon secretion from α cells, contribute to the hyperglycemia in T2D. While many hypotheses
and models exist, the molecular mechanisms responsible for human islet dysfunction in T2D are incompletely
defined and largely unknown or unproven. Most models and hypotheses about the T2D β cell arise from
studies of rodent models and have not been confirmed or tested in human samples. Because of the many
differences in human and rodent islets, it is critical to study potential regulators in a human islet context and
that will be a focus of this proposal. This proposed studies are based on evidence that islets from donors with
short-duration T2D have impaired insulin secretion, enhanced glucagon secretion, and reduced expression of
PAX6, an islet-enriched transcription factor recently shown in rodent systems critical to islet β cell identify and
functional maintenance. Very little is known about the role of PAX6 is human islet cells. The proposed studies
will test the hypothesis that PAX6 is required for normal human α and β cell function and that reduced PAX6
expression contributes to T2D islet α and β cell dysfunction in these aims: (1) Determine the functional and
transcriptional consequences of PAX6 transcriptional control normal human islets in vitro; (2) Determine the
functional consequences of PAX6 loss from normal human α or β cells in vivo; (3) Assess whether PAX6 loss
in short-duration T2D islets is reversed by treatment with a Glucagon-like Peptide-1 (GLP-1) agonist. By
employing innovative experimental approaches such as creation of human pseudoislets in which gene
expression can be modified and transplantation of genetically modified human pseudoislets into
immunodeficient, glucagon-less mouse model (NSG-GKO) to allow for the assessment of α and β cell function
in vitro and in vivo, these studies will expand our understanding of the molecular processes regulating human
α and β cell function and islet dysfunction, leading to new clinically actionable information for T2D treatment.
2型糖尿病(T2 D)是VA医疗保健系统面临的一个巨大且不断增长的挑战,
涉及胰岛素分泌受损、胰岛素抵抗和
肝葡萄糖生成增加。β细胞胰岛素分泌不足和失调,通常
α细胞胰高血糖素分泌增加,导致T2 D高血糖症。虽然许多假设
尽管存在模型,但T2 D中人类胰岛功能障碍的分子机制尚不完全
定义和大部分未知或未经证实。关于T2 D β细胞的大多数模型和假设来自于
在啮齿类动物模型中进行的研究,尚未在人类样本中得到证实或测试。由于许多
由于人类和啮齿动物胰岛的差异,研究人类胰岛背景下的潜在调节剂至关重要,
这将是本提案的一个重点。这项拟议的研究是基于证据,即来自供体的胰岛,
短持续时间T2 D具有受损的胰岛素分泌、增强的胰高血糖素分泌和降低的
PAX 6,一种最近在啮齿动物系统中显示的对胰岛β细胞鉴定至关重要的胰岛富集转录因子,
功能维护关于PAX 6在人类胰岛细胞中的作用知之甚少。拟议的研究
将检验PAX 6是正常人α和β细胞功能所必需的假设,
表达有助于T2 D胰岛α和β细胞功能障碍,这些目的是:(1)确定功能和
PAX 6转录控制正常人胰岛的体外转录结果;(2)确定PAX 6转录控制正常人胰岛的体外转录结果。
体内正常人α或β细胞PAX 6损失的功能后果;(3)评估PAX 6损失是否
在短期T2 D胰岛中,通过用胰高血糖素样肽-1(GLP-1)激动剂处理而逆转。通过
采用创新的实验方法,如建立人类假胰岛,其中基因
表达可以被修饰,并且将遗传修饰的人假胰岛移植到
免疫缺陷、无胰高血糖素小鼠模型(NSG-GKO),用于评估α和β细胞功能
在体外和体内,这些研究将扩大我们的理解的分子过程调节人类
α和β细胞功能和胰岛功能障碍,为T2 D治疗提供新的临床可操作信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALVIN C POWERS其他文献
ALVIN C POWERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALVIN C POWERS', 18)}}的其他基金
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
-- - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
-- - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)